Published in J Immunol on June 15, 2003
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 3.45
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Systemic effects of local radiotherapy. Lancet Oncol (2009) 2.97
Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res (2011) 1.82
Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol (2012) 1.76
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res (2008) 1.59
The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol (2012) 1.44
In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol (2012) 1.43
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology (2014) 1.39
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) (2008) 1.38
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res (2006) 1.36
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev (2015) 1.22
Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J Immunother (2008) 1.18
Local control by radiotherapy: is that all there is? Breast Cancer Res (2008) 1.18
Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm (2012) 1.16
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res (2008) 1.14
Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine (2007) 1.13
Role of T lymphocytes in tumor response to radiotherapy. Front Oncol (2012) 1.12
The effect of radiation on the immune response to cancers. Int J Mol Sci (2014) 1.03
Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol (2010) 1.02
Combinations of immunotherapy and radiation in cancer therapy. Front Oncol (2014) 1.01
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology (2013) 0.98
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res (2015) 0.98
Regulatory T cells in radiotherapeutic responses. Front Oncol (2012) 0.98
Enhancement of antitumor immunity by low-dose total body irradiationis associated with selectively decreasing the proportion and number of T regulatory cells. Cell Mol Immunol (2010) 0.97
Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. J Immunother (2009) 0.97
Clinical development of Listeria monocytogenes-based immunotherapies. Semin Oncol (2012) 0.95
Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol (2015) 0.92
Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci (2009) 0.92
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine (2015) 0.92
Organizing pneumonia after stereotactic ablative radiotherapy of the lung. Radiat Oncol (2012) 0.92
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene (2013) 0.91
Promising novel immunotherapies and combinations for prostate cancer. Future Oncol (2009) 0.91
Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol (2014) 0.91
Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res (2014) 0.90
Immune modulation and stereotactic radiation: improving local and abscopal responses. Biomed Res Int (2013) 0.90
Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med (2014) 0.90
Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets. Br J Cancer (2014) 0.89
Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther (2012) 0.88
Radiation as immunomodulator: implications for dendritic cell-based immunotherapy. Radiat Res (2014) 0.87
High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up. J Radiat Res (2013) 0.87
Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines (2014) 0.86
Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways. PLoS One (2012) 0.86
Vaccines as monotherapy and in combination therapy for prostate cancer. Clin Transl Sci (2010) 0.85
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park) (2015) 0.85
Does the mobilization of circulating tumour cells during cancer therapy cause metastasis? Nat Rev Clin Oncol (2016) 0.84
Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res (2011) 0.84
Up-regulation of Fas (CD95) expression in tumour cells in vivo. Immunology (2007) 0.84
Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine (2011) 0.84
Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl (2014) 0.84
Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer. World J Gastrointest Oncol (2010) 0.84
In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer. Mol Cancer Ther (2012) 0.84
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J (2013) 0.84
Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells. Mol Ther (2010) 0.83
mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol (2014) 0.83
The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer (2010) 0.83
Combining Vaccines with Conventional Therapies for Cancer. Update Cancer Ther (2007) 0.82
Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model. Clin Immunol (2008) 0.82
Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. Mol Ther (2009) 0.82
Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation? Transl Lung Cancer Res (2016) 0.81
Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells. J Immunother Cancer (2013) 0.81
Considerations for combined immune checkpoint modulation and radiation treatment. Radiat Res (2014) 0.81
New drugs in prostate cancer. Prostate Int (2016) 0.80
Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice. J Immunother (2013) 0.80
A model of dendritic cell therapy for melanoma. Front Oncol (2013) 0.80
Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors. Cancer Immunol Immunother (2007) 0.79
Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Cancer Immunol Immunother (2016) 0.79
Emerging Treatment Paradigms in Radiation Oncology. Clin Cancer Res (2015) 0.79
Cancer vaccines: current directions and perspectives in prostate cancer. Curr Opin Mol Ther (2009) 0.78
CpG Oligodeoxynucleotides Enhance the Activities of CD8+ Cytotoxic T-Lymphocytes Generated by Combined hMUC1 Vaccination and hNIS Radioiodine Gene Therapy. Nucl Med Mol Imaging (2010) 0.78
Variant splicing and influence of ionizing radiation on human endogenous retrovirus K (HERV-K) transcripts in cancer cell lines. PLoS One (2013) 0.78
Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy. Oncoimmunology (2014) 0.77
Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin. Oncotarget (2016) 0.77
DICE: A novel tumor surveillance mechanism-a new therapy for cancer? Cell Cycle (2014) 0.77
Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol (2012) 0.77
Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack. J Immunother Cancer (2015) 0.77
Immunomodulatory effects of radiation: what is next for cancer therapy? Future Oncol (2015) 0.77
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. J Immunol Res (2016) 0.76
The combination of ANT2 shRNA and hNIS radioiodine gene therapy increases CTL cytotoxic activity through the phenotypic modulation of cancer cells: combination treatment with ANT2 shRNA and I-131. BMC Cancer (2013) 0.76
Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy. PLoS One (2015) 0.76
Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction. PLoS One (2015) 0.76
Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol (2015) 0.76
NF-κB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. Oncotarget (2016) 0.75
Intercellular Communication of Tumor Cells and Immune Cells after Exposure to Different Ionizing Radiation Qualities. Front Immunol (2017) 0.75
Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12. Hum Vaccin Immunother (2016) 0.75
The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer? Curr Breast Cancer Rep (2017) 0.75
Barriers to Radiation-Induced In Situ Tumor Vaccination. Front Immunol (2017) 0.75
A Century of Radiation Therapy and Adaptive Immunity. Front Immunol (2017) 0.75
Radiation meets immunotherapy - a perfect match in the era of combination therapy? Int J Radiat Biol (2015) 0.75
Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade. BMC Res Notes (2016) 0.75
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. Immunotherapy (2011) 0.75
Current perspectives in prostate cancer vaccines. Anticancer Agents Med Chem (2009) 0.75
Special topics in immunotherapy and radiation therapy: reirradiation and palliation. Transl Lung Cancer Res (2017) 0.75
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol (2003) 11.94
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2008) 8.79
Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med (2004) 5.63
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 4.25
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol (2003) 3.70
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res (2004) 2.91
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys (2012) 2.55
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res (2004) 2.54
Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res (2004) 2.33
Autophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemia-reperfusion injury. Am J Pathol (2010) 2.24
HDAC inhibitors in cancer care. Oncology (Williston Park) (2010) 2.20
Current status and future potential of advanced technologies in radiation oncology. Part 2. State of the science by anatomic site. Oncology (Williston Park) (2009) 2.08
Radiologic and nuclear events: contingency planning for hematologists/oncologists. Blood (2008) 1.96
Transrectal prostate biopsy and fiducial marker placement in a standard 1.5T magnetic resonance imaging scanner. J Urol (2006) 1.96
Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems. Disaster Med Public Health Prep (2011) 1.93
Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res (2007) 1.91
GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res (2009) 1.89
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res (2008) 1.83
Transcriptional signature of flavopiridol-induced tumor cell death. Mol Cancer Ther (2004) 1.80
Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proc Natl Acad Sci U S A (2005) 1.77
Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res (2002) 1.77
Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res (2009) 1.74
CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res (2009) 1.72
System for prostate brachytherapy and biopsy in a standard 1.5 T MRI scanner. Magn Reson Med (2004) 1.71
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res (2009) 1.69
Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res (2006) 1.68
Rapid radiation dose assessment for radiological public health emergencies: roles of NIAID and BARDA. Health Phys (2010) 1.65
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res (2006) 1.61
Radiation injury after a nuclear detonation: medical consequences and the need for scarce resources allocation. Disaster Med Public Health Prep (2011) 1.60
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res (2008) 1.59
Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. Proc Natl Acad Sci U S A (2013) 1.58
The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol (2009) 1.56
Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer (2005) 1.56
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One (2011) 1.55
Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res (2003) 1.53
Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res (2005) 1.49
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget (2014) 1.49
MRI-guided HDR prostate brachytherapy in standard 1.5T scanner. Int J Radiat Oncol Biol Phys (2004) 1.44
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res (2009) 1.44
Walking forward: the South Dakota Native American project. J Cancer Educ (2005) 1.44
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2005) 1.44
In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol (2012) 1.43
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res (2009) 1.40
Are radiation oncologists serious about systemic radiation therapy and if not, should we be? Int J Radiat Oncol Biol Phys (2004) 1.39
Radiation-induced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes. Cancer Res (2006) 1.38
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res (2006) 1.36
Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol (2007) 1.36
Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol (2003) 1.34
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer (2011) 1.34
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest (2013) 1.33
Epigenetics and colorectal cancer pathogenesis. Cancers (Basel) (2013) 1.33
Disaster preparation: lessons from Japan. Science (2011) 1.30
In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res (2008) 1.29
Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8. J Gastrointest Surg (2009) 1.28
Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res (2007) 1.27
Three-color labeling method for flow cytometric measurement of cytogenetic damage in rodent and human blood. Environ Mol Mutagen (2004) 1.27
NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. J Biol Chem (2012) 1.24
Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res (2004) 1.23
The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia (2012) 1.23
Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res (2003) 1.22
Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin Cancer Res (2010) 1.22
Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol (2004) 1.21
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res (2005) 1.20
The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. J Immunol (2003) 1.19
Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother (2011) 1.18
A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. Oncology (2011) 1.18
Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res (2006) 1.18
Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol (2012) 1.18
Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst (2006) 1.17
Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res (2004) 1.17
Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A (2013) 1.17
Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood (2007) 1.17
Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination? Mol Biosyst (2009) 1.16
Biological dosimetry by the triage dicentric chromosome assay: potential implications for treatment of acute radiation syndrome in radiological mass casualties. Radiat Res (2011) 1.16
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res (2013) 1.16
Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res (2013) 1.15